DALIRESP Market Summary

Key Factors Driving DALIRESP Growth

1. Unique oral PDE4 inhibitor mechanism in severe COPD

DALIRESP remains the only approved oral selective PDE4 inhibitor specifically indicated to reduce COPD exacerbations in severe COPD patients with chronic bronchitis and a history of exacerbations. Unlike inhaled bronchodilators, roflumilast targets systemic inflammatory pathways involved in COPD progression. AstraZeneca highlighted that the drug has a “unique position” as the only PDE4 inhibitor proven to reduce exacerbation rates in difficult-to-treat COPD patients already receiving inhaled therapies.

2. Growing severe COPD population and high unmet need

COPD continues to represent one of the world’s largest chronic respiratory disease burdens. Severe COPD patients with frequent exacerbations remain at particularly high risk for hospitalization, lung-function decline, and mortality. DALIRESP is commonly positioned as an add-on therapy for patients who remain symptomatic despite dual or triple inhaled therapy. AstraZeneca specifically emphasized the drug’s role in patients still experiencing exacerbations despite optimized inhaled regimens.

3. Add-on benefit alongside dual and triple inhaled therapies

One of DALIRESP’s major growth drivers is its compatibility with modern COPD combination regimens. Clinical evidence cited during AstraZeneca’s acquisition of Takeda’s respiratory business showed roflumilast reduced exacerbations when added to dual bronchodilator and free-triple inhaled therapies. As triple therapy use expands globally, the pool of severe patients eligible for adjunctive anti-inflammatory treatment may also increase.

4. Strategic integration into AstraZeneca’s respiratory franchise

AstraZeneca acquired global rights to DALIRESP/DAXAS through its US$575 million acquisition of Takeda’s respiratory business in 2015. The company viewed the drug as strategically important for strengthening its severe COPD portfolio alongside inhaled respiratory therapies. AstraZeneca stated the acquisition would support its “return to growth strategy” and be immediately accretive to earnings.

DALIRESP Recent Developments

European marketing approval received in 2010 as Daxas (nycomed); a first-in-class selective PDE4 inhibitor for COPD.

“DALIRESP Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of DALIRESP for approved indication like Chronic obstructive pulmonary disease in the 7MM. A detailed picture of DALIRESP’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the DALIRESP for approved indications. The DALIRESP market report provides insights about DALIRESP’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current DALIRESP performance, future market assessments inclusive of the DALIRESP market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of DALIRESP sales forecasts, along with factors driving its market.

DALIRESP Drug Summary

DALIRESP is an oral selective phosphodiesterase-4 (PDE4) inhibitor developed by AstraZeneca for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. Containing the active ingredient roflumilast, DALIRESP works by reducing inflammation in the airways through inhibition of PDE4, leading to decreased production of pro-inflammatory mediators rather than direct bronchodilation. The once-daily oral therapy is primarily used as an add-on treatment to bronchodilators in patients at high risk of COPD exacerbations, where clinical studies have shown reductions in moderate-to-severe exacerbation rates and improvements in lung function. DALIRESP has become an important anti-inflammatory option in advanced COPD management, particularly for patients with chronic bronchitis phenotypes inadequately controlled on inhaled therapies alone. The report provides DALIRESP’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the DALIRESP Market Report

The report provides insights into:

• A comprehensive product overview including the DALIRESP MoA, description, dosage and administration, research and development activities in approved indication like Chronic obstructive pulmonary disease.
• Elaborated details on DALIRESP regulatory milestones and other development activities have been provided in DALIRESP market report.
• The report also highlights DALIRESP‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The DALIRESP market report also covers the patents information, generic entry and impact on cost cut.
• The DALIRESP market report contains current and forecasted DALIRESP sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The DALIRESP market report also features the SWOT analysis with analyst views for DALIRESP in approved indications.

Methodology

The DALIRESP market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DALIRESP Analytical Perspective by DelveInsight

• In-depth DALIRESP Market Assessment

This DALIRESP sales market forecast report provides a detailed market assessment of DALIRESP for approved indication like Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted DALIRESP sales data uptil 2034.

• DALIRESP Clinical Assessment

The DALIRESP market report provides the clinical trials information of DALIRESP for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

DALIRESP Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

DALIRESP Market Potential & Revenue Forecast

• Projected market size for the DALIRESP and its key indications
• Estimated DALIRESP sales potential (DALIRESP peak sales forecasts)
• DALIRESP Pricing strategies and reimbursement landscape

DALIRESP Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• DALIRESP Market positioning compared to existing treatments
• DALIRESP Strengths & weaknesses relative to competitors

DALIRESP Regulatory & Commercial Milestones

• DALIRESP Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

DALIRESP Clinical Differentiation

• DALIRESP Efficacy & safety advantages over existing drugs
• DALIRESP Unique selling points

DALIRESP Market Report Highlights

• In the coming years, the DALIRESP market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The DALIRESP companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DALIRESP’s dominance.
• Other emerging products for Chronic obstructive pulmonary disease are expected to give tough market competition to DALIRESP and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DALIRESP in approved indications.
• Analyse DALIRESP cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted DALIRESP sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of DALIRESP in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of DALIRESP? How strong is DALIRESP’s clinical and commercial performance?
• What is DALIRESP’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DALIRESP Manufacturers?
• What are the key designations that have been granted to DALIRESP for approved indications? How are they going to impact DALIRESP’s penetration in various geographies?
• What is the current and forecasted DALIRESP market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of DALIRESP in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DALIRESP for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is DALIRESP? What is the duration of therapy and what are the geographical variations in cost per patient?